Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Bluejay Diagnostics Inc

BJDX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$2.29

▲ +3.62%

Market Cap $2.56M · Vol 30.00K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.56M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

21.17

Momentum

Beta

0.99

vs Market

52W High

$28.32

91.91% below

52W Low

$1.84

24.40% above

Volume

30.00K

Avg 13.98K

P/B

0.07

Price-to-book

ROE

N/A

Return on equity

Free Float

97.97%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Bluejay Diagnostics Inc (BJDX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BJDX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.58%

-31.57%

-42.75%

-70.49%

YTD

-78.55%

-92.00%

-99.99%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-6,848,480.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-99.42% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.07
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.12M

Technical Indicators

50-Day SMA	$3.20
200-Day SMA	$7.26
RSI (14)	21.17
Beta	0.99
52-Week High	$28.32
52-Week Low	$1.84

Volume Today	30.00K
Avg Daily Volume (30D)	13.98K
Relative Volume	2.15x
Volatility (10D)	69.50
Volatility (30D)	67.57
Free Float	97.97%

Analyst Consensus

N/A

Current Price $2.29

Mean Target N/A

52W Low$1.84 52W High$28.32

Current

Target

$1.84 $28.32

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG012TKJDC6

ISINUS0956336087

CountryUSA

Sub-IndustryBio Diagnostics & Testing

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

CDNA CareDx, Inc. -2.95% ADPT Adaptive Biotechnologies Corporation +3.53% VCYT Veracyte, Inc. +4.43% IOVA Iovance Biotherapeutics Inc -1.47% 300676.SZ BGI Genomics Co Ltd +3.00%

Company Profile

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.